Next Article in Journal
Detection of Mycosphaerella graminicola in Wheat Leaves by a Microsatellite Dinucleotide Specific-Primer
Next Article in Special Issue
MALDI Imaging Mass Spectrometry (MALDI-IMS)―Application of Spatial Proteomics for Ovarian Cancer Classification and Diagnosis
Previous Article in Journal
Herbaceous Peony (Paeonia lactiflora Pall.) as an Alternative Source of Oleanolic and Ursolic Acids
Previous Article in Special Issue
Exploring the Immunoproteome for Ovarian Cancer Biomarker Discovery
Article Menu

Export Article

Open AccessArticle
Int. J. Mol. Sci. 2011, 12(1), 668-681; doi:10.3390/ijms12010668

Combined Effects of Cyclooxygenase-1 and Cyclooxygenase-2 Selective Inhibitors on Ovarian Carcinoma in Vivo

Department of Gynecology, Nanjing Medical University of Hangzhou Hospital, 261 Huansha Road, Hangzhou, Zhejiang 310006, China
*
Author to whom correspondence should be addressed.
Received: 30 November 2010 / Revised: 28 December 2010 / Accepted: 10 January 2011 / Published: 18 January 2011
(This article belongs to the Special Issue Cancer Molecules in Ovarian Cancer)
View Full-Text   |   Download PDF [308 KB, uploaded 19 June 2014]   |  

Abstract

The present study was designed to investigate the combined effects of cyclooxygenase (COX)-1 and COX-2 selective inhibitors on human ovarian SKOV-3 carcinoma cells xenograft-bearing mice. The animals were treated with 3 mg/kg SC-560 (a COX-1 selective inhibitor) alone, 25 mg/kg celecoxib (a COX-2 selective inhibitor) alone, or SC-560/celecoxib by gavage, twice a day for three weeks. To test the mechanism of inhibition of tumor growth by COX selective inhibitors, the index of proliferating cells in tumor tissues was determined by immunostaining and the index of apoptotic cells by the terminal-deoxynucleotidyl-transferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL) method. The inhibitory rate on tumor growth in the combination group was 35.54% which is significant statistically compared with that of the control group (P < 0.05). In the combination group, the index of cell proliferation and apoptosis were 12.40% and 51.03% respectively, which are significant statistically compared with those of the control group (22.56%, 19.07%, all P < 0.05). These studies indicate that synergism between two COX inhibitors and inhibitor combination treatment has particular potential for chemoprevention of ovarian cancer growth. View Full-Text
Keywords: ovarian carcinoma; mice; cyclooxygenase selective inhibitor; cell proliferation; apoptosis ovarian carcinoma; mice; cyclooxygenase selective inhibitor; cell proliferation; apoptosis
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Li, W.; Wang, J.; Jiang, H.-R.; Xu, X.-L.; Zhang, J.; Liu, M.-L.; Zhai, L.-Y. Combined Effects of Cyclooxygenase-1 and Cyclooxygenase-2 Selective Inhibitors on Ovarian Carcinoma in Vivo. Int. J. Mol. Sci. 2011, 12, 668-681.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top